)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Protara Therapeutics
Protara Therapeutics (TARA) investor relations material
Protara Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
Pipeline programs include TARA-002 for NMIBC and lymphatic malformations (LMs), and IV Choline Chloride for patients receiving parenteral support; no product sales revenue has been generated.
Q3 2026 net loss was $21.7M versus $13.3M a year earlier; cash, cash equivalents and marketable debt securities totaled $143.1M at September 30.
November 4 acquisition of TARA-002 manufacturing assets from Novex for $8.75M is intended to bring manufacturing in-house and secure capacity ahead of a potential launch.
ADVANCED-2 enrollment is targeted to finish by year-end 2026, STARBORN-1 enrollment early Q1 2027, and THRIVE-3 interim results in Q4 2026.
Financial highlights
Q3 operating expenses and operating loss were each $23.2M versus $14.8M a year earlier; net loss was $21.7M versus $13.3M.
Q3 R&D expense was $16.8M versus $9.6M YoY; G&A was $6.3M versus $5.2M.
9M operating expenses were $66.1M versus $45.5M; net loss was $61.1M versus $40.1M.
9M R&D expense rose to $47.3M from $29.5M; G&A increased to $18.8M from $16.0M.
9M other income, net, was $5.0M versus $5.3M; prior-year results included $0.5M of nonrecurring refundable tax credits, partly offset by higher 2026 investment income.
Outlook and guidance
ADVANCED-2 BCG-Unresponsive cohort enrollment is expected to finish in Q4 2026; enrollment is complete in the 31-patient BCG-Naïve cohort.
THRIVE-3 interim dose-confirmation results are anticipated in Q4 2026; its 24-patient open-label phase completed enrollment in October.
STARBORN-1 enrollment is targeted for early Q1 2027; a rolling BLA for TARA-002 in LMs is planned to begin in H2 2027.
Cash resources are expected to fund planned operations and milestones into 2028; additional capital will be needed to fully execute plans.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Protara Therapeutics
- TARA-002 demonstrates robust efficacy and safety in pivotal trials, with major milestones ahead.TARA
H.C. Wainwright 28th Annual Global Investment Conference - Key clinical milestones are on track, with $161.9M in cash and a Q2 net loss of $21.7M.TARAQ2 2026
- TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts.TARA7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- TARA-002 achieved 100% clinical success in evaluable LM patients with no serious adverse events.TARAKOL event
- Biopharma launches $100M ATM offering to fund late-stage cancer and rare disease trials.TARARegistration filing
- Net loss reached $17.8M as R&D spending rose; $177.4M in cash supports runway into 2028.TARAQ1 2026
- Key votes include director elections, auditor ratification, and major charter amendments.TARAProxy filing
- 100% six-month complete response achieved in BCG-unresponsive NMIBC with strong safety.TARAStudy Update
- TARA-002 and IV choline advance with strong efficacy, safety, and major 2025 milestones ahead.TARA43rd Annual J.P. Morgan Healthcare Conference 2025
Next Protara Therapeutics earnings date
Q4 20269 Mar, 2027
Protara Therapeutics
Next Protara Therapeutics earnings date
Q4 20269 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. Their lead program, TARA-002, is an investigational cell therapy aimed at treating lymphatic malformations, based on the broad immunopotentiator OK-432. Additionally, Protara is developing intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. The company is headquartered in NYC, and its shares are listed on the Nasdaq.